Hepatitis Monthly

Published by: Kowsar

Real World Experience with All-Oral Interferon Free Regimen for the Treatment of Lebanese Patients with Hepatitis C Virus (HCV) Infection

Antoine Abou Rached 1 , 2 , * , Jowana Saba 1 , Cesar Yaghi 3 , Ala Sharara 4 and Walid Ammar 2
Authors Information
1 Lebanese University, School of Medicine, Beirut, Lebanon
2 Ministry of Public Health, Beirut, Lebanon
3 Saint Joseph University, School of Medicine, Beirut, Lebanon
4 American University of Beirut, School of Medicine, Beirut, Lebanon
Article information
  • Hepatitis Monthly: August 2018, 18 (8); e69040
  • Published Online: June 27, 2018
  • Article Type: Research Article
  • Received: April 21, 2018
  • Revised: June 11, 2018
  • Accepted: June 16, 2018
  • DOI: 10.5812/hepatmon.69040

To Cite: Abou Rached A, Saba J, Yaghi C, Sharara A, Ammar W. et al. Real World Experience with All-Oral Interferon Free Regimen for the Treatment of Lebanese Patients with Hepatitis C Virus (HCV) Infection, Hepat Mon. 2018 ; 18(8):e69040. doi: 10.5812/hepatmon.69040.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
References
  • 1. WHO. Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version. Geneva: WHO Guidelines Approved by the Guidelines Review Committee; 2016.
  • 2. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58-68. doi: 10.1016/j.jhep.2014.07.012. [PubMed: 25443346].
  • 3. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081-8. doi: 10.1016/S0140-6736(16)30579-7. [PubMed: 27394647]. [PubMed Central: PMC5100695].
  • 4. Hiramatsu N, Oze T, Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res. 2015;45(2):152-61. doi: 10.1111/hepr.12393. [PubMed: 25052449].
  • 5. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-93. doi: 10.1001/jama.2012.144878. [PubMed: 23268517].
  • 6. LSGE. The 14th annual congress of Lebanese society of gastroenterology. 2012. Available from: http://www.lsge.org/index.php?id=meetings&name=Meetings&type=meetings.
  • 7. Abou Rached A, Abou Kheir S, Saba J, Ammar W. Epidemiology of hepatitis B and hepatitis C in Lebanon. Arab J Gastroenterol. 2016;17(1):29-33. doi: 10.1016/j.ajg.2016.01.002. [PubMed: 27032492].
  • 8. Abou Rached A, Yaghi C, Khalil L, Saba J, Ammar W. Prevalence of hepatitis C virus genotypes and subtypes in Lebanese population and major high risk groups. Arab J Gastroenterol. 2017;18(2):114-7. doi: 10.1016/j.ajg.2017.05.001. [PubMed: 28579342].
  • 9. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology. 2016;64(2):405-14. doi: 10.1002/hep.28625. [PubMed: 27115523].
  • 10. Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, et al. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. Gastroenterology. 2016;151(6):1131-1140 e5. doi: 10.1053/j.gastro.2016.08.004. [PubMed: 27565882]. [PubMed Central: PMC5300778].
  • 11. Welzel TM, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S, et al. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. J Viral Hepat. 2017;24(10):840-9. doi: 10.1111/jvh.12708. [PubMed: 28342229].
  • 12. Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarebska-Michaluk D, Nazzal K, et al. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther. 2016;44(9):946-56. doi: 10.1111/apt.13790. [PubMed: 27611776].
  • 13. Wedemeyer H, Craxi A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK, et al. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir+/-dasabuvir+/-ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. J Viral Hepat. 2017;24(11):936-43. doi: 10.1111/jvh.12722. [PubMed: 28480525].
  • 14. Calleja JL, Crespo J, Rincon D, Ruiz-Antoran B, Fernandez I, Perello C, et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. J Hepatol. 2017;66(6):1138-48. doi: 10.1016/j.jhep.2017.01.028. [PubMed: 28189751].
  • 15. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Comparative effectiveness of ledipasvir/sofosbuvir +/- ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther. 2016;44(4):400-10. doi: 10.1111/apt.13696. [PubMed: 27291852].
  • 16. Walker DR, Pedrosa MC, Manthena SR, Patel N, Marx SE. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV). Adv Ther. 2015;32(11):1117-27. doi: 10.1007/s12325-015-0258-5. [PubMed: 26538232]. [PubMed Central: PMC4662718].
  • 17. Crespo J, Calleja JL, Fernandez I, Sacristan B, Ruiz-Antoran B, Ampuero J, et al. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. Clin Gastroenterol Hepatol. 2017;15(6):945-949 e1. doi: 10.1016/j.cgh.2017.02.020. [PubMed: 28238958].
  • 18. Wehmeyer MH, Ingiliz P, Christensen S, Hueppe D, Lutz T, Simon KG, et al. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03). J Med Virol. 2018;90(2):304-12. doi: 10.1002/jmv.24903. [PubMed: 28710853].
  • 19. Schulze Zur Wiesch J, Pudelski N, Hoepner L, Supplieth M, Buggisch P, Lohse AW, et al. "Real-Life" comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus. Hepatology. 2011;53(4):1405-6. author reply 1407. doi: 10.1002/hep.24185. [PubMed: 21480360].
  • 20. Heidrich B, Cordes HJ, Klinker H, Moller B, Naumann U, Rossle M, et al. Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial. PLoS One. 2015;10(6). e0128069. doi: 10.1371/journal.pone.0128069. [PubMed: 26057627]. [PubMed Central: PMC4461366].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments